{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:30:45Z","timestamp":1791822645976,"version":"4.3.4"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T00:00:00Z","timestamp":1663891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.aohep.2022.100762","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T02:09:35Z","timestamp":1664417375000},"page":"100762","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysis"],"prefix":"10.1016","volume":"28","author":[{"given":"Mark","family":"Muthiah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8297-1569","authenticated-orcid":false,"given":"Cheng Han","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai En","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarissa Elysia","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen Hui","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren Jun Hao","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Nah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwyneth","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieling","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie Ning","family":"Yong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Syn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7986-6082","authenticated-orcid":false,"given":"Jiong-Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilofer","family":"Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas WS","family":"Chew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7546-2117","authenticated-orcid":false,"given":"Yock Young","family":"Dan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Shadab","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun J.","family":"Sanyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen","family":"Noureddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.aohep.2022.100762_bib0001","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","article-title":"Nonalcoholic fatty liver disease 2020: the state of the disease","volume":"158","author":"Cotter","year":"2020","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.aohep.2022.100762_bib0002","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of non-alcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2022.100762_bib0003","article-title":"An observational data meta-analysis on the differences in prevalence and risk factors between MAFLD vs NAFLD","author":"Lim","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2022.100762_bib0004","doi-asserted-by":"crossref","DOI":"10.1007\/s11883-022-01027-5","article-title":"Comprehensive review and updates on holistic approach towards non-alcoholic fatty liver disease management with cardiovascular disease","author":"Chew","year":"2022","journal-title":"Curr Atheroscler Rep"},{"issue":"4","key":"10.1016\/j.aohep.2022.100762_bib0005","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(22)00078-X","article-title":"Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis","volume":"23","author":"Tan","year":"2022","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.aohep.2022.100762_bib0006","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"International Consensus P. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2022.100762_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.eprac.2022.03.016","article-title":"Metabolic associated fatty liver disease increases the risk of systemic complications and mortality. a meta-analysis and systematic review of 12 620 736 individuals","author":"Quek","year":"2022","journal-title":"Endocrine Pract"},{"issue":"4","key":"10.1016\/j.aohep.2022.100762_bib0008","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S2213-8587(22)00003-1","article-title":"A global view of the interplay between non-alcoholic fatty liver disease and diabetes","volume":"10","author":"Stefan","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.aohep.2022.100762_bib0009","doi-asserted-by":"crossref","DOI":"10.3350\/cmh.2022.0096","article-title":"The effect of diabetes and prediabetes on the prevalence, complications and mortality in non-alcoholic fatty liver disease","author":"Ng","year":"2022","journal-title":"Clinic Mol Hepatol"},{"key":"10.1016\/j.aohep.2022.100762_bib0010","article-title":"Global NAFLD prevalence: a systematic review and meta-analysis","author":"Le","year":"2019","journal-title":"Clin Gastroenterol Hepatol 2021"},{"issue":"4","key":"10.1016\/j.aohep.2022.100762_bib0011","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2022.100762_bib0012","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgac321","article-title":"Global prevalence and clinical characteristics of metabolic associated fatty liver disease. a meta-analysis and systematic review of 10,739,607 individuals","author":"Chan","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.aohep.2022.100762_bib0013","unstructured":"CDC. National Health and Nutrition Examination Survey (NHANES). 2017;2020, https:\/\/wwwn.cdc.gov\/nchs\/nhanes\/continuousnhanes\/default.aspx?BeginYear=2017."},{"key":"10.1016\/j.aohep.2022.100762_bib0014","year":"2017","journal-title":"Centers Dis Control Prevent"},{"key":"10.1016\/j.aohep.2022.100762_bib0015","doi-asserted-by":"crossref","unstructured":"Noureddin M, Ntanios F, Malhotra D, Hoover K, Emir B, McLeod E, et al. Predicting NAFLD prevalence in the United States using National Health and Nutrition Examination Survey 2017-2018 transient elastography data and application of machine learning. Hepatol Commun 2022. https:\/\/doi.org\/10.1002\/hep4.1935.","DOI":"10.1002\/hep4.1935"},{"issue":"1","key":"10.1016\/j.aohep.2022.100762_bib0016","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.aohep.2022.100762_bib0017","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"issue":"9403","key":"10.1016\/j.aohep.2022.100762_bib0018","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0140-6736(03)15268-3","article-title":"Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies","volume":"363","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.aohep.2022.100762_bib0019","doi-asserted-by":"crossref","DOI":"10.1002\/hep4.1981","article-title":"Non-alcoholic fatty liver disease prevalence and severity in Asian Americans from the national health and nutrition examination surveys 2017-2018","author":"Truong","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.aohep.2022.100762_bib0020","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-230X-6-33","article-title":"The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population","volume":"6","author":"Bedogni","year":"2006","journal-title":"BMC Gastroenterol"},{"issue":"38 Suppl","key":"10.1016\/j.aohep.2022.100762_bib0021","first-page":"S4","article-title":"Standards of medical care in diabetes\u20132015: summary of revisions","year":"2015","journal-title":"Diabetes Care"},{"issue":"33","key":"10.1016\/j.aohep.2022.100762_bib0022","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"issue":"9811","key":"10.1016\/j.aohep.2022.100762_bib0023","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(11)60178-5","article-title":"Chronic kidney disease","volume":"379","author":"Levey","year":"2012","journal-title":"Lancet"},{"issue":"S2","key":"10.1016\/j.aohep.2022.100762_bib0024","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/dom.14521","article-title":"A clinical overview of non-alcoholic fatty liver disease: A guide to diagnosis, the clinical features, and complications\u2014What the non-specialist needs to know","volume":"24","author":"Muthiah","year":"2022","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1016\/j.aohep.2022.100762_bib0025","doi-asserted-by":"crossref","DOI":"10.3350\/cmh.2022.0070","article-title":"NAFLD versus MAFLD: prevalence, outcomes and implications of a change in name","author":"Ng","year":"2022","journal-title":"Clin Mol Hepatol"},{"issue":"11","key":"10.1016\/j.aohep.2022.100762_bib0026","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1111\/liv.14623","article-title":"Concordance between MAFLD and NAFLD diagnostic criteria in 'real-world' data","volume":"40","author":"Targher","year":"2020","journal-title":"Liver Int"},{"issue":"9","key":"10.1016\/j.aohep.2022.100762_bib0027","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41575-021-00448-y","article-title":"The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments","volume":"18","author":"Targher","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"16","key":"10.1016\/j.aohep.2022.100762_bib0028","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMra011775","article-title":"Nonalcoholic fatty liver disease","volume":"346","author":"Angulo","year":"2002","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.aohep.2022.100762_bib0029","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1586\/erc.11.15","article-title":"Hepatic steatosis and Type 2 diabetes: current and future treatment considerations","volume":"9","author":"Richard","year":"2011","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"4","key":"10.1016\/j.aohep.2022.100762_bib0030","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.jhep.2021.06.013","article-title":"Are the different MAFLD subtypes based on the inclusion criteria correlated with all-cause mortality?","volume":"75","author":"Chen","year":"2021","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.aohep.2022.100762_bib0031","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.tem.2021.04.008","article-title":"Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease","volume":"32","author":"Lim","year":"2021","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.aohep.2022.100762_bib0032","article-title":"NAFLD or MAFLD: which has closer association with all-cause and cause-specific mortality?-Results From NHANES III","volume":"8","author":"Huang","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.aohep.2022.100762_bib0033","article-title":"The prevalence and determinants of NAFLD and MAFLD and their severity in the va primary care setting","author":"Thrift","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.aohep.2022.100762_bib0034","doi-asserted-by":"crossref","first-page":"230","DOI":"10.14218\/JCTH.2021.00306","article-title":"Metabolic dysfunction-associated fatty liver disease is associated with greater impairment of lung function than nonalcoholic fatty liver disease","volume":"10","author":"Miao","year":"2022","journal-title":"J Clin Transl Hepatol"},{"issue":"4","key":"10.1016\/j.aohep.2022.100762_bib0035","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jhep.2020.12.016","article-title":"Clinical utility of the MAFLD definition","volume":"74","author":"Zheng","year":"2021","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.aohep.2022.100762_bib0036","article-title":"Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B","volume":"3","author":"van Kleef","year":"2021","journal-title":"JHEP Rep"},{"issue":"1","key":"10.1016\/j.aohep.2022.100762_bib0037","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/apt.16706","article-title":"Increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis with concurrent fatty liver","volume":"55","author":"Kim","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.aohep.2022.100762_bib0038","doi-asserted-by":"crossref","DOI":"10.1002\/hep.32499","article-title":"Are there outcome differences between NAFLD and metabolic-associated fatty liver disease?","author":"Younossi","year":"2022","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.aohep.2022.100762_bib0039","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S2468-1253(22)00062-0","article-title":"Global multi-stakeholder endorsement of the MAFLD definition","volume":"7","author":"Mendez-Sanchez","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2022.100762_bib0040","article-title":"Sodium-glucose co-transporter 2 inhibitors for non-alcoholic fatty liver disease in asian patients with type 2 diabetes: a meta-analysis","volume":"11","author":"Wong","year":"2020","journal-title":"Front Endocrinol"},{"issue":"2","key":"10.1016\/j.aohep.2022.100762_bib0041","doi-asserted-by":"crossref","DOI":"10.3390\/metabo11020073","article-title":"Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials","volume":"11","author":"Mantovani","year":"2021","journal-title":"Metabolites"},{"issue":"2","key":"10.1016\/j.aohep.2022.100762_bib0042","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.eprac.2021.09.013","article-title":"Anti-diabetic medications for type 2 diabetics with nonalcoholic fatty liver disease: evidence from a network meta-analysis of randomized controlled trials","volume":"28","author":"Ng","year":"2022","journal-title":"Endocr Pract"},{"issue":"2","key":"10.1016\/j.aohep.2022.100762_bib0043","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1161\/HYPERTENSIONAHA.120.15220","article-title":"Nonalcoholic fatty liver disease and advanced fibrosis in us adults across blood pressure categories","volume":"76","author":"Ciardullo","year":"2020","journal-title":"Hypertension"},{"issue":"11","key":"10.1016\/j.aohep.2022.100762_bib0044","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1002\/oby.23263","article-title":"Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and non-alcoholic fatty liver disease","volume":"29","author":"Barb","year":"2021","journal-title":"Obesity"},{"issue":"6","key":"10.1016\/j.aohep.2022.100762_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2020.07.023","article-title":"Physical activity, measured objectively, is associated with lower mortality in patients with nonalcoholic fatty liver disease","volume":"19","author":"Kim","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.aohep.2022.100762_bib0046","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1111\/apt.12963","article-title":"Performance and limitations of steatosis biomarkers in patients with non-alcoholic fatty liver disease","volume":"40","author":"Fedchuk","year":"2014","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268122001041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268122001041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:44:46Z","timestamp":1761648286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268122001041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S1665268122001041"],"URL":"https:\/\/doi.org\/10.1016\/j.aohep.2022.100762","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysis","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aohep.2022.100762","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"100762"}}